e3112
Recombinant proteinexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 25, 2017 (NCT03014895)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hepatocyte growth factorSupplementation
HGF supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- e3112
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03922633 | Phase 1 | Apr 22, 2019 | EA Pharma Co., Ltd. |
| NCT03014895 | Early Phase 1 (Phase 1) | Jan 25, 2017 | EA Pharma Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| EA Pharma Co., Ltd. | For profit | 2 | 2 | 1 | 2017 |
1 organizations
Page 1 / 1